RenovoRx's $12.1 Million Offering: Fueling Innovation in Targeted Oncology Therapies

RenovoRx, Inc. (Nasdaq: RNXT), a clinical-stage biopharmaceutical company specializing in developing novel targeted oncology therapies, has announced the pricing of its underwritten public offering. The company aims to raise approximately $12.1 million through the sale of shares of its common stock at a price of $1.05 per share. All shares in the offering will be sold by RenovoRx, with Titan Partners Group, a division of American Capital Partners, acting as the sole bookrunner.

RenovoRx's innovative approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy in cancer patients. The company's patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform is designed to ensure precise therapeutic delivery across the arterial wall near the tumor site, minimizing toxicities compared to systemic intravenous therapy. RenovoRx's Phase III lead product candidate, RenovoGem, is a novel oncology drug-device combination product that utilizes the company's FDA-cleared RenovoCath drug-delivery device for the treatment of locally advanced pancreatic cancer (LAPC).

The net proceeds from the offering will be used for working capital and general corporate purposes, including the continued progression of RenovoRx's Phase III TIGeR-PaC study and the continued development and execution of commercial sales and marketing activities for RenovoCath as a standalone device. The TIGeR-PaC study is a pivotal Phase III clinical trial evaluating RenovoGem for the treatment of LAPC, while RenovoCath is an FDA-cleared delivery platform that RenovoRx is commercializing as a standalone device.

RenovoRx's innovative approach to targeted oncology therapies has shown promising clinical data, extending pancreatic cancer survival rate by 5 months and improving quality of life. The company's market cap of $70M is undervalued compared to its peers, with an EV/EBITDA ratio of 0.925, which is relatively low. This offering provides an opportunity for investors to participate in the growth of a company that is transforming the lives of cancer patients by providing innovative solutions for targeted delivery of diagnostic and therapeutic agents.



RenovoRx's innovative approach to targeted oncology therapies has shown promising clinical data, extending pancreatic cancer survival rate by 5 months and improving quality of life. The company's market cap of $70M is undervalued compared to its peers, with an EV/EBITDA ratio of 0.925, which is relatively low. This offering provides an opportunity for investors to participate in the growth of a company that is transforming the lives of cancer patients by providing innovative solutions for targeted delivery of diagnostic and therapeutic agents.



In conclusion, RenovoRx's $12.1 million public offering is an exciting opportunity for investors to support a company that is at the forefront of targeted oncology therapies. With a strong pipeline, promising clinical data, and a undervalued market cap, RenovoRx is well-positioned to continue its growth and make a significant impact on the lives of cancer patients.